e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

VanEck Biotech ETF (NQ:BBH)

192.72 +3.10 (+1.64%)

Streaming Delayed Price Updated: 11:20 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about VanEck Biotech ETF

Time For Gilead Sciences-Heavy ETFs? ↗

September 12, 2023

Gilead Sciences has underperformed the broader market this year by a hefty margin.

Via Talk Markets

Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention ↗

April 13, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of...

Via Benzinga

Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules ↗

April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.

Via Benzinga

New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications ↗

April 12, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this...

Via Benzinga

Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead ↗

April 11, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating...

Via Benzinga

FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits ↗

April 06, 2023

Via Benzinga

US Judge Weighs Nationwide Ban On Abortion Pills ↗

March 16, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is...

Via Benzinga

FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug' ↗

March 01, 2023

Via Benzinga

3 Best Funds for Aggressive Investors ↗

August 11, 2022

These are the three best funds for aggressive investors. ETFs like BUG, RYT, and BBH can make great investments in the rest of the year.

Via InvestorPlace

Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money ↗

June 22, 2022

With an economic hurricane on the horizon, investors are searching for alternative investment paths and profitable places to invest in.

Via InvestorPlace

Progenity Is Unlikely to Live Up to Its IPO Hype ↗

December 15, 2021

Progenity went public in June 2020. Eighteen months later, PROG stock has lost 83% of its value. Is there any hope for this fading biotech?

Via InvestorPlace

How Are Biotech ETFs Reacting To These Q3 Earnings Releases? ↗

November 06, 2021

There's no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines. Let’s take a look at big biotech earnings releases to see...

Via Talk Markets

Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone ↗

November 01, 2021

After the formidable run, NVAX stock has come under significant pressure, but between its pipeline and its Covid vaccine, it is a dip buy.

Via InvestorPlace

Take A Look At The Top-Performing Biotech ETFs YTD ↗

October 02, 2021

The biotechnology sector has been grabbing the headlines on the new coronavirus vaccine and drug-related updates. The space has also kept its promise of generating returns, with the Nasdaq...

Via Talk Markets

Biotech ETFs To Benefit From Latest Booster Update ↗

August 21, 2021

Vaccine makers like Moderna and Pfizer have reasons to cheer the update with regard to the application of boosters. The U.S. government announced plans to make COVID-19 vaccine boosters available from...

Via Talk Markets

ETF Investing Areas to Consider for August ↗

August 09, 2021

There is no doubt that the second-quarter 2021 earnings season is going strong.

Via Talk Markets

Moderna ETFs To Rise On Positive COVID-19 Vaccine Updates ↗

July 03, 2021

The competition to come up with a vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to...

Via Talk Markets

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

Here is a look at five ETFs with large exposure to Biogen shares.

Via Talk Markets

5 Top ETFs With Exposure To Biogen ↗

June 07, 2021

For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that...

Via Benzinga

Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines ↗

May 08, 2021

The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from...

Via Talk Markets

Topics Intellectual Property

Moderna Stock Moves After Q1 Print: Technical Levels For The COVID-19 Vaccine Play ↗

May 06, 2021

Moderna Inc. (NASDAQ: MRNA) shares gapped down Thursday and have since gained back some ground. Moderna reported first-quarter earnings Thursday of $2.84 per share, beating the...

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy